#50 What The July FDA Hearing Could Mean For Compounded Peptides
About this episode
The episode discusses the implications of the July FDA hearing on compounded peptides and patient access.
The internet loves a scary headline, and “peptides placed in category two” might be the most misunderstood one yet. We’re Dr. Kylie Burton and Jessica Briecke, and we’re slowing the noise down to explain what’s actually happening with the FDA’s July 23–24 hearing and why it directly affects patient access to compounded peptides. It started back in 2023 when compounding pharmacies pushed back against government regulation. What happened then and what's happening now revolves around the FDA's ...
People in this episode
Hosts: Dr. Kylie Burton, Jessica Briecke
Topics covered
- FDA hearing
- compounded peptides
- patient access
- government regulation
- pharmacy pushback
Keywords
- peptides
- FDA
- compounding pharmacies
- patient access
- government regulation
Mentioned in this episode
Organizations: FDA
More episodes of Peptalk: Peptides Unpacked
- #57 Reclaiming Desire, Rebuilding Connection: Jen's experience on PT-141 and Marriage
- #56 Unlearning the Standard of Care: Dr. Joelle Osias (a Gynecologist) Makes the Case for Peptides and Root-Cause Healing
- #55 Better Sleep, More Energy, Stronger Bones: The Gentle Peptide For Menopausal Women
- #54 Callie's Miracle: An Unexpected Path to Pregnancy
- #53 The Peptide Combo For Beat-Up Bodies: The Wolverine Stack
- #52 For GLP-1 Skeptics (and Lovers): They do Much More than Assist with Weight Loss
Explore listener stats, chart rankings, contacts and more on the Peptalk: Peptides Unpacked podcast page.